NASDAQ$ETON
Eton Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Eton Pharmaceuticals reported its second quarter 2025 financial results, highlighting significant revenue growth driven by strong product sales and strategic launches.
Eton Pharmaceuticals delivered impressive second-quarter results, with total net revenues reaching $18.9 million, a 108% increase year-over-year, primarily fueled by strong product sales of ALKINDI SPRINKLE, INCRELEX, and GALZIN. The company achieved non-GAAP diluted EPS of $0.03 and significantly improved its Adjusted EBITDA to $3.1 million. Key operational successes included the FDA approval and launch of KHINDIVI, reaching 100 active INCRELEX patients ahead of schedule, and advancing its pipeline programs.
- Total net revenues for Q2 2025 were $18.9 million, marking a 108% increase compared to Q2 2024.
- Product sales and royalties reached $18.9 million, representing the 18th consecutive quarter of sequential growth.
- GAAP diluted EPS was $(0.10), while non-GAAP diluted EPS was $0.03, indicating improved profitability on an adjusted basis.
- Adjusted EBITDA significantly improved to $3.1 million from $(1.6) million in the prior year period.
Headline financials
Revenue & EPS history
Eton · Revenue · Quarterly
$18.9M
Revenue by segment
Eton · $24.3M total across 1 segment · Q1 2026
- Product Sales and Royalties$24.3M—100.0%
Forward guidance
Eton Pharmaceuticals anticipates continued strong performance, projecting to achieve an $80 million annual revenue run rate in Q3 2025, one quarter ahead of previous guidance. The company also expects Adjusted G&A expenses to remain flat or decline through the second half of 2025 and is preparing for the potential approval and launch of ET-600 in Q1 2026.
Tailwinds
- Expected to achieve an $80 million annual revenue run rate in Q3 2025, one quarter ahead of previous guidance.
- Anticipates Adjusted G&A expenses to remain flat or decline through the second half of 2025.
- NDA for ET-600 accepted by the FDA with a Target Action Date of February 25, 2026, with commercialization activities already underway.
- Working to develop a new formulation for KHINDIVI for patients aged four years and under, with a pre-submission meeting with the FDA scheduled for September.
- Expects to file a supplement to the existing KHINDIVI NDA in the first half of 2026, potentially allowing for approval before the end of 2026.
Headwinds
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company continues to operate at a GAAP net loss, although it is improving.
- Future success is dependent on regulatory approvals and market adoption of new products.
- Competition in the rare disease market remains a factor.
- Potential for unforeseen challenges in product development and commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+0.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
48%
15 / 31 earnings
Positive
+36.0%
Q2 2023
Best reaction
-14.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +6.7% | — | |
| Q4 2025 | +7.5% | +14.8% | +20.6% | |
| Q3 2025 | -11.4% | -8.8% | -15.0% | |
| Q2 2025 | +12.5% | +12.2% | +15.8% | |
| Q1 2025 | +0.4% | +14.6% | -16.2% | |
| Q4 2024 | -4.0% | -7.0% | -6.2% | |
| Q3 2024 | +9.2% | +3.2% | +25.2% | |
| Q2 2024 | +6.6% | +8.0% | +31.5% | |
| Q1 2024 | -7.8% | -2.4% | -3.0% | |
| Q4 2023 | -14.1% | -21.0% | -23.7% | |
| Q3 2023 | -13.7% | -16.6% | -19.1% | |
| Q2 2023 | +36.0% | +79.5% | +83.7% | |
| Q1 2023 | +2.8% | +2.6% | +10.3% | |
| Q4 2022 | +2.6% | +7.1% | -7.4% | |
| Q3 2022 | +18.5% | +20.9% | +22.8% | |
| Q2 2022 | -1.0% | -19.4% | -22.8% | |
| Q1 2022 | +1.3% | +6.5% | -4.9% | |
| Q4 2021 | +6.1% | +8.7% | -1.5% | |
| Q3 2021 | -3.4% | -9.2% | -20.7% | |
| Q2 2021 | -5.0% | -0.2% | +12.7% | |
| Q1 2021 | +5.2% | +7.5% | -13.4% | |
| Q4 2020 | -0.7% | -1.1% | +5.9% | |
| Q3 2020 | -1.5% | +2.9% | +19.9% | |
| Q2 2020 | -2.2% | +4.4% | +12.4% | |
| Q1 2020 | -9.2% | -10.3% | -1.1% | |
| Q4 2019 | -8.4% | -21.9% | -39.8% | |
| Q3 2019 | +1.9% | +2.3% | +9.2% | |
| Q2 2019 | +1.6% | -1.8% | -14.2% | |
| Q1 2019 | +3.2% | +12.2% | +5.9% | |
| Q4 2018 | -2.3% | +2.6% | -5.8% | |
| Q3 2018 | -8.1% | -4.8% | -3.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro